|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
11 September 2017 |
|
Main ID: |
ChiCTR-IOR-17012626 |
|
Date of registration:
|
2017-09-09 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Effect and Safety Evaluation of anti-EGFR therapy combined local therapy for unresectable colonrectal cancer Chinese Patients
|
|
Scientific title:
|
Effect and Safety Evaluation of anti-EGFR therapy combined local therapy for unresectable colonrectal cancer Chinese Patients |
|
Date of first enrolment:
|
2017-09-18 |
|
Target sample size:
|
Intervention Group:120;Control Group:60; |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=21313 |
|
Study type:
|
Interventional study |
|
Study design:
|
Randomized parallel controlled trial
|
|
Phase:
|
Other
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Zhou Bo
|
|
Address:
|
180 Fenglin Road, Shanghai, China
200032
|
|
Telephone:
|
+86 13621604953 |
|
Email:
|
zhou.bo@zs-hospital.sh.cn |
|
Affiliation:
|
Fudan University Zhongshan Hospital |
|
|
Name:
|
Zhou Bo
|
|
Address:
|
180 Fenglin Road, Shanghai, China
200032
|
|
Telephone:
|
+86 13621604953 |
|
Email:
|
zhou.bo@zs-hospital.sh.cn |
|
Affiliation:
|
Fudan University Zhongshan Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Patients with colonrectal cancer liver metastasis, and RAS wild type;
2. No jaundice obstructive;
3. Patients are willing to take cetuximab;
4. Patients are willing to join the research, to accept the informed consent, to privide specimen;
5. Aged above 18 years and lower than 80 years;
6. The lesion can be measured.
Exclusion criteria: 1. Patients who can be followed.
2. Patients who have no ability to determination
3. Patients are taking other targeted therapy.
4. Patients with severe organ funtion disorders.
5. Survival time lower than 3 months
6. Intolerant or allergic to cetuximab
7. Contraindications for cetuximab
Age minimum:
18
Age maximum:
80
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
colonrectal cancer liver metastasis
|
|
Intervention(s)
|
|
Intervention Group:chemotherapy and target therapy combined TACE;Control Group:chemotherapy and target therapy;
|
|
Primary Outcome(s)
|
|
Image Evaluation;
|
|
Source(s) of Monetary Support
|
|
Fund by Chinese Society of Clinical Oncology, CSCO
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|